08th week of 2015 patent applcation highlights part 32 |
Patent application number | Title | Published |
20150050189 | AIR PURIFICATION DEVICE FOR VEHICLE - The invention relates to an air purification device for a vehicle and has an object to provide a DOR (Direct Ozone Reduction) system that can improve durability of activated carbon as an ozone purifier. FIG. | 2015-02-19 |
20150050190 | MODULAR DUCTWORK DECONTAMINATION ASSEMBLY - A modular ductwork assembly decontaminates an air stream circulating within a heating, ventilation and air conditioning (HVAC) system. The assembly includes one or more of (a) an ionizing module for removing particulates from the air stream, (b) a sterilization module for neutralizing airborne pathogens present in the air stream, (c) an ozone treatment module for neutralizing pathogens or odoriferous or gaseous constituents or volatile organic compounds (VOCs) present in the air stream, optionally (d) baffles for slowing and disrupting the flow rate and promoting turbulence in the air stream traveling through the modules, optionally (e) a fan module for directing a treated air stream, optionally (f) an ozone sensor, optionally (g) a monitoring or ozone control means, and optionally (h) a means of delivering and repurposing generated ozone. Each of the modules is arranged substantially adjacent to at least one of the other modules. | 2015-02-19 |
20150050191 | Plasma Driven Catalyst System for Disinfection and Purification of Gases - The present invention relates to a novel plasma driven catalyst apparatus for disinfecting and purifying air. The apparatus has a synergistically favorable effect from plasma and catalyst on high disinfecting and purifying efficiency and efficacy, low by-product formation, and low energy consumption. The plasma combined with catalyst enhances the production of new active species, increases the oxidizing power of the plasma discharge, as well as activate the catalyst that additionally contributes towards the disinfection and purification process and the elimination of toxic by-products. | 2015-02-19 |
20150050192 | Activated Carbon Manufacturing System - An activated carbon manufacturing system can efficiently heat a wood material or carbide to promote a drying process, a carbonization process and an activation process in manufacturing activated carbon, and can reduce the environmental load involved in the manufacture of activated carbon. Specifically, a drying process of a wood material is achieved by heating the wood material with saturated steam at an appropriate temperature, and an initial carbonization process of the wood material is achieved by heating the wood material with superheated steam. Therefore, the wood material can be heated with high heat transfer efficiency, so that the heat loss can be reduced, and neither a drying device nor a first carbonizing device produces a gas containing a harmful constituent in the heating processes, so that the adverse effect on the environment can be reduced. | 2015-02-19 |
20150050193 | SYSTEM FOR MANUFACTURING GRAPHENE NANORIBBON BY CONTINUOUS MICROWAVE - A system for manufacturing graphene nanoribbon by continuous microwave is disclosed. The system comprises a microwave heating tank for heating carbon nanotube through microwave, a reaction tank for adding an oxidizing or reducing agent and a pipeline for connecting all devices of the system. A feed rate is controlled by a pump to enter raw material into the system via the pipeline, the nanotube is made to be a graphene nanoribbon by heating, adding the oxidizing agent, reheating, adding the reducing agent and reheating. Therefore, the graphene nanoribbon could be mass produced automatically in a short time. | 2015-02-19 |
20150050194 | DEVICE FOR STERILIZING ICE MACHINE USING OZONE GAS FROM ELECTROLYTIC OZONE GENERATOR - A device for sterilizing an ice machine using ozone gas from an electrolytic ozone generator includes a pure water tank ( | 2015-02-19 |
20150050195 | CHLORINE ANALYTICAL TEST ELEMENT AND A STABILIZED N, N-DIETHYL-P-PHENYLENEDIAMINE SOLUTION - A test element ( | 2015-02-19 |
20150050196 | COLORIMETRIC INDICATORS FOR USE IN MEDICAL DEVICES - A colorimetric time indicator configured to indicate time specificity is provided. The colorimetric time indicator includes a colorimetric layer configured to be operatively coupled to a disposable medical device. The colorimetric time indicator is configured to indicate the time specificity via one or more visual indicators upon exposure to one or more external stimuli. | 2015-02-19 |
20150050197 | BRAKE MECHANISM FOR AN ELECTRONIC PIPETTE - For use in an electronic pipette, a brake mechanism which is used for abruptly stopping the movement of the actuator that moves the plunger, which mechanism comprises a rotatable, essentially circular rotor that is at its periphery provided with brake notches arranged at regular intervals, and a brake actuator comprising a motion inducing means, a brake member ( | 2015-02-19 |
20150050198 | DEVICE WITH DISPLAY FOR REPEATED DOSING - A dosing device comprises a housing. The housing has a slot-shaped opening in the axial direction. The respective region of a setting cylinder located inside the housing can be seen from the exterior through the opening. The setting cylinder can be radially rotated or set by way of a setting wheel. Quantitative indications of the discharge volumes for various syringe types at various settings are arranged in columns on the setting cylinder in the form of a table. The cylinder is oriented relative to the window in the housing such that at a given angular setting of the cylinder the correct discharge volume is visible in the window for every syringe type. | 2015-02-19 |
20150050199 | REMOVAL OF LEAD FROM SOLID MATERIALS - A leaching composition that substantially removes lead from solid materials and a method of using said composition. Preferably, the concentration of lead in the solid materials following processing is low enough that the solid materials can be reused and/or disposed of at minimal cost to the processor. Preferably, the solid materials comprise glass, such as cathode ray tube glass. | 2015-02-19 |
20150050200 | PRODUCTION METHOD FOR HEMATITE FOR IRON PRODUCTION - Provided is a production method for refining iron oxide (hematite), which has such a low sulfur content as to be used as a raw material for ironmaking from a leach residue containing iron oxide, the leach residue being produced by a high pressure acid leach (HPAL) process and being a raw material that can be cheaply and stably procured. In the method of producing (high purity) hematite for ironmaking by a process of adding an oxidant and sulfuric acid to nickel oxide ore and then leaching nickel, a leach residue obtained after the leaching of nickel is heated to 600° C. or more, and preferably 800° C. or more and 1400° C. or less. | 2015-02-19 |
20150050201 | METHOD FOR PRODUCING HEMATITE FOR IRONMAKING - Provided is a production method for refining iron oxide (hematite), which has such a low sulfur content as to be used as an iron-making raw material, from a leach residue containing iron oxide produced by a high pressure acid leach (HPAL) process. In the method for refining iron oxide for ironmaking by a process of adding sulfuric acid to nickel oxide ore and then leaching nickel from the nickel oxide ore using a pressure vessel, an amount of the sulfuric acid added is 150 kg or more and 220 kg or less per ton of nickel oxide ore. | 2015-02-19 |
20150050202 | METHOD TO REDUCE MERCURY, ACID GAS, AND PARTICULATE EMISSIONS - A method is provided in which a contaminated waste gas, comprising particulates, an acid gas, and mercury, is contacted with a mercury removal agent to remove or cause the removal of mercury from the waste gas and a flue gas conditioning agent to alter at least one of a resistivity and cohesivity of the particulates. At least one of the following statements is true: the flue gas conditioning agent is substantially free of SO | 2015-02-19 |
20150050203 | SYSTEM AND PROCESS FOR CAPTURE OF ACID GASSES AT ELEVATED PRESSURE FROM GASEOUS PROCESS STREAMS - A system, method, and material that enables the pressure-activated reversible chemical capture of acid gasses such as CO | 2015-02-19 |
20150050204 | CATALYST FOR SELECTIVE OXIDATION OF SULPHUR COMPOUNDS - The present invention is related to a catalyst supported for the selective oxidation of sulphur compounds of the tail gas from the Claus process or streams with an equivalent composition to elemental sulphur or sulphur dioxide (SO | 2015-02-19 |
20150050205 | CONTAINER CONTAINING A COBALT CARBONYL COMPLEX AND COBALT CARBONYL COMPLEX COMPOSITION - A container containing a cobalt carbonyl complex and a gas that contains carbon monoxide, and a cobalt carbonyl complex composition comprising a cobalt carbonyl complex and a solvent, wherein the concentration of carbon monoxide dissolved in the solvent is 0.001 to 1 wt %. | 2015-02-19 |
20150050206 | METHOD OF PREPARING CALCIUM CARBONATE USING DIRECT CARBONATION REACTION - Disclosed is a method of preparing calcium carbonate using a direct carbonation reaction. The method includes dissolving fuel gas desulfurization gypsum into an ammonia solution, performing a filtering process after making a carbonation reaction by feeding carbon dioxide into the ammonia solution in which the fuel gas desulfurization gypsum is dissolved, and performing a filtering process after precipitating the calcium carbonate by maintaining a filtered solution in a stationary state. | 2015-02-19 |
20150050207 | DETONATION NANODIAMOND MATERIAL PURIFICATION METHOD AND PRODUCT THEREOF - A mild, acid- and alkali-free purification method of detonation nanodiamond material from water-insoluble metal-containing impurities and product obtained thereof. The products thus obtained include nanodiamond and diamond-containing detonation blend. The method is implemented by an impact treatment of the detonation nanodiamond material with aqueous or water organic solutions of chelating agents in concentrations 0.5-20 wt. % at elevated temperature, wherein the weight-percent ratio of the detonation nanodiamond material to an undiluted chelating agent is substantially 1 to 0.2. Impact treatment of the detonation nanodiamond material in chelating agent solution may include boiling, ultrasonication, cavitational disintegration, and harsh treatment in sealed chamber at temperatures of up to about 300° C. and high pressure. The method provides at least 5-fold reduction of metal-containing impurities in the resulting product, wherein the content of such elements as chromium and iron is reduced to negligible amounts. | 2015-02-19 |
20150050208 | Enzyme-Mediated Assimilation of DNA-Functionalized Single-Walled Carbon Nanotubes (SWNTs) - Select embodiments of the present invention employ biological means to direct assemble CNT-based nanostructures, allowing for scaling to macrostructures for manufacture. In select embodiments of the present invention, a method is provided for assembling DNA-functionalized SWNTs by phosphodiester bonding catalyzed by ssDNA-ligase to form macroscopic CNT aggregates. | 2015-02-19 |
20150050209 | PRODUCTION METHOD OF MAYENITE - The present invention provides a production method of mayenite in which mayenite can be produced without requiring a high-temperature treatment, and the cost of equipment and heating cost are inexpensive, and in its turn, the production cost of mayenite is inexpensive. The production method of mayenite is characterized in that mayenite (Ca | 2015-02-19 |
20150050210 | PHARMACEUTICAL FORMULATION COMPRISING BENDAMUSTINE - The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives. The invention further relates to a process for preparing a pharmaceutical composition which comprises bendamustine and its derivatives prepared by hot melt extrusion using pharmaceutically acceptable excipients. The invention also relates to such pharmaceutical compositions and hot melt extrudates. | 2015-02-19 |
20150050211 | METHODS FOR PREPARING HIGH THROUGHPUT PEPTIDOMIMETICS, ORALLY BIOAVAILABLE DRUGS AND COMPOSITIONS CONTAINING SAME - Provided herein are methods to generate and screen peptides that exhibit drug like stabilities in vitro and in vivo. By selecting for enzyme resistance, Applicants are able to derive peptides that are not only stable to a broad spectrum of proteases, but also stable to other drug processing enzymes such as cytochrome P450s. This approach provides a general method to the rapid development of highly stable peptides for therapeutic development and diagnosis. The peptides are further modified for oral bioavailability. The methods can be applied to similar peptides for the making of therapeutic compositions | 2015-02-19 |
20150050212 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY - Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer. | 2015-02-19 |
20150050213 | COMPOSITIONS AND METHODS FOR IMAGING INFLAMMATION OF TRAUMATIC BRAIN INJURY - The present application provides compositions and methods for imaging traumatic brain injury using PET. The present application discloses using PET ligands targeting infiltrating neutrophils, such as a ligand of FPR, is useful for imaging inflammation. In one aspect, the ligand and imaging agent cFLFLF-PEG- | 2015-02-19 |
20150050214 | COMPOSITION AND METHOD OF MAKING THE NOVEL 3D POLYMER GEL FOR USE IN RADIATION TREATMENT PLANNING - Polymer gel dosimeters based on radiation-induced polymerization of N-(Isobutoxymethyl) acrylamide (NIBMA) polymer gels in normal atmospheric condition (NIBMAGAT) have been synthesized and studied as a new composition of polymer gel dosimeters for radiotherapy treatment planning. The dosimeters were irradiated with at absorbed doses up to 30 Gy and no change in dose response was observed even after using repeatedly for eight times. The novel composition shows no change in the relaxation rate or absorbance of the gel dosimeters up to 144 hours. Dose response of NIBMAGAT gel dosimeters increases with increase of monomer concentration. The relaxation rate of NIBMAGAT gel increases with increase of THPC concentration from 2.5 to 5 mM, but the dose response is not affected with increase of THPC concentration from 5 to 20 mM. The results show that the dose sensitivity increases significantly with increase of glycerol concentration up to ≈30% within gel dosimeters. | 2015-02-19 |
20150050215 | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE - The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein. | 2015-02-19 |
20150050216 | Uses and Compositions for Treatment of Psoriasis - The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject. | 2015-02-19 |
20150050217 | ULTRAFINE NANOPARTICLES AS MULTIMODAL CONTRAST AGENT - The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors. | 2015-02-19 |
20150050218 | Dynamic Contrast Enhanced MRI Method And Agents For The Assessment Of The Macromolecular Transport Within Pathologic Tissues - The present invention generally relates to paramagnetic contrast agents and a Dynamic Contrast Enhanced-MRI method for the non-invasive estimation of the delivery of a macromolecular anticancer drug or pro-drug within pathological tissues and, especially, in solid tumors and for the optimization of anticancer therapies. | 2015-02-19 |
20150050219 | COLOURED SOLUTION IN PARTICULAR FOR USE IN SURGICAL METHODS FOR THE TREATMENT OF THE BODIES OF HUMANS OR ANIMALS - First, a coloured solution is claimed, comprising at least one perfluorocarbon as a solvent and a dye dissolved in the perfluorocarbon and selected from the family of fluorinated derivatives of phthalocyanines obtained by substituting one or more of the hydrogen H atoms linked to the benzene rings with a fluorine atom or a fluorinated group, for use in surgical methods for the treatment of the bodies of humans or animals, in particular in surgical methods of vitreoretinal surgery where the coloured solution acts as a retinal tamponade. Second, a coloured solution is claimed, comprising at least one perfluorocarbon selected from perfluorooctane, perfluorodecalin and perfluorophenanthrene as a solvent and a dye dissolved in the perfluorocarbon and selected from the family indicated above. The dye, in general, is preferably selected from the family of metalpoly(fluoroalkyl)phthalocyanines and even more preferably of metalpoly(perfluoroalkyl)phthalocyanines. | 2015-02-19 |
20150050220 | ANTIMICROBIAL COMPOSITION - The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, p-menthene alcohols and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants. | 2015-02-19 |
20150050221 | Compositions and Methods for the Maintenance of Oral Health - The invention provides compositions comprising one or more isolated LDH-deficient | 2015-02-19 |
20150050222 | GLUCOSYL STEVIA COMPOSITION - Glucosyl stevia compositions are prepared from steviol glycosides of | 2015-02-19 |
20150050223 | NOVEL PHOTOPROTECTIVE SYSTEM - The present invention concerns a topical, cosmetic or pharmaceutical preparation containing a combination of 3 or 4 solar filters comprising: —one or two UVA filters to obtain a critical wavelength >370 nm, chosen from among: (i)—5,6,5,6-tetraphenyl-3,3′-(1,4-phenylene)-bis[1,2,4]triazine; (ii) 1,1′-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone; (iii)—Butyl Methoxydibenzoylmethane (BMDBM), in a quantity less than 2% by weight with regard to the total weight of said composition; (iv)—Hexyl-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, -2,4-Bis[4-(2-ethyl-hexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine=(BEMT), —one or two filters chosen from among UVB filters, except octocrylene, PABA and ethylhexyl methoxycinnamate, said composition also containing a pharmaceutically or cosmetically acceptable excipient. | 2015-02-19 |
20150050224 | COSMETIC AND PHARMACEUTICAL USES OF SACCHARIDES - The present invention provides cosmetic and pharmaceutical compositions and therapies capable of reducing skin pigmentation and valuable in treating and managing disorders of skin pigmentation. The invention uses safe and well tolerated non-digestible oligosaccharides as the active agents providing numerous advantages over the harsh chemicals of previously available compositions. | 2015-02-19 |
20150050225 | TOPICAL SUNSCREEN COMPOSITIONS - Substantially anhydrous compositions including at least 10% by weight of a C | 2015-02-19 |
20150050226 | THERAPEUTIC VITAMIN D SUN-PROTECTING FORMULATIONS AND METHODS FOR THEIR USE - The present invention concerns topical sun-protecting formulations including therapeutically effective amounts of Vitamin D, including formulations that provide Vitamin D in bioavailable amounts that correspond to decreased natural Vitamin D production resulting from the sun-blocking effects of the formulations and formulations for the prevention and treatment of disorders and disease states associated with vitamin D deficiency and vitamin D insufficiency. | 2015-02-19 |
20150050227 | Compositions Having Perspiration Reduction Properties - A composition containing polymeric microparticles is disclosed. The composition effectively reduces perspiration in the absence of aluminum/zirconium antiperspirant compounds. | 2015-02-19 |
20150050228 | HAIR TREATMENT AGENT CONTAINING SELECTED FATTY ACID AMIDES AND SELECTED OIL BODIES - The present invention relates to hair treatment agents containing a synergistic combination of selected fatty acid amides and oil bodies selected from ester oils and vegetable oils. | 2015-02-19 |
20150050229 | HAIR TREATMENT AGENTS CONTAINING SELECTED FATTY ACID AMIDES AND SELECTED UV FILTERS - The present invention relates to hair treatment agents including a synergistic combination of selected fatty acid amides and further selected hydroxycarboxylic acids. | 2015-02-19 |
20150050230 | Compositions and Methods for Treating Damaged Hair - Compositions and methods are disclosed for repairing damaged keratin fibers or otherwise strengthening keratin fibers, including hair of the human scalp, and particularly hair that has been damaged chemically, physically, thermally or by other means. The compositions comprise 3,3′-thiodipropionic acid (TDPA) or a derivative thereof in a cosmetically acceptable vehicle. | 2015-02-19 |
20150050231 | HAIR COSMETIC - It is an object of the present invention to provide a hair cosmetic achieving a hair-setting property without causing flaking and further having an excellent hair-rearranging property and non-stickiness. The hair cosmetic of the present invention includes the following components (A) to (D):
| 2015-02-19 |
20150050232 | MARINE ANTIFOULING COATING - A marine antifouling coating comprising a hydrophobic polymeric material formed by reacting a mixture comprising at least one ethylene propylene diene terpolymer, wherein the terpolymer component comprises from 4 weight percent to 50 weight percent of random covalently linked monomers of ethylene and propylene and 0.25 weight percent to 15 weight percent of the polymer component is a non-conjugated diene, a first co-agent of polybutadiene, a second co-agent of an acrylate or methacrylate in a solvent with at least one peroxide. The marine antifouling coating is used for application to a surface of a marine vessel. | 2015-02-19 |
20150050233 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES - The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula: | 2015-02-19 |
20150050234 | POLYMERIC COMPOSITE MATERIALS WITH ANTIMICROBIAL AND BIODEGRADABLE PROPERTIES AND USES THEREOF - A composite material for the production of a medical device having an antiseptic action includes a matrix of alginate in which the complex of iodopovidone is dispersed. The composite material is used particularly for the production of films, micro-capsules, and suture threads with iodine controlled release. | 2015-02-19 |
20150050235 | COMPOSITION FOR ATTRACTING MALE BLUEBERRY SPANWORM MOTH - A composition that includes: Z,Z-(3R,4S)-cis-3,4-epoxy-6,9-heptadecadiene; and Z,Z,Z-3,6,9-heptadecatriene, where the Z,Z-(3R,4S)-cis-3,4-epoxy-6,9-heptadecadiene and the Z,Z,Z-3,6,9-heptadecatriene are present in a ratio of between 5:1 (by mass) and about 20:1 (by mass). The composition may be for attracting a male blueberry spanworm moth. Use of a composition that includes Z,Z-(3R,4S)-cis-3,4-epoxy-6,9-heptadecadiene and Z,Z,Z-3,6,9-heptadecatriene for attracting male blueberry spanworm. A method of attracting male blueberry spanworm moths that includes placing a composition comprising Z,Z-(3R,4S)-cis-3,4-epoxy-6,9-heptadecadiene and Z,Z,Z-3,6,9-heptadecatriene suitably close to a field of having the male blueberry spanworm moths. | 2015-02-19 |
20150050236 | COMPOSITION FOR ATTRACTING MALE BLUEBERRY SPANWORM MOTH - A method of attracting male blueberry spanworm moths that includes placing a composition comprising Z,Z-(3R,4S)-cis-3,4-epoxy-6,9-heptadecadiene and Z,Z,Z-3,6,9-heptadecatriene suitably close to a field of having the male blueberry spanworm moths. Use of a composition that includes Z,Z-(3R,4S)-cis-3,4-epoxy-6,9-heptadecadiene and Z,Z,Z-3,6,9-heptadecatriene for attracting male blueberry spanworm. The components may be present in a ratio of between 5:1 (by mass) and about 20:1 (by mass). | 2015-02-19 |
20150050237 | NEW ANTI-MYCOBACTERIAL DRUGS AGAINST TUBERCULOSIS - The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy. | 2015-02-19 |
20150050238 | TREATMENT OF OSTEOARTHRITIS AND PAIN - The present invention relates to the treatment of osteoarthritis and pain using IL-1α and IL-1β binding proteins, including anti-IL-1α and anti-IL-1β antibodies and engineered multivalent and multispecific IL-1α and IL-1β binding proteins. | 2015-02-19 |
20150050239 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE - The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans. | 2015-02-19 |
20150050240 | TREATMENT OF FIBROSIS - This invention is in the field of treatment of fibrosis. In particular, it relates to the treatment of IPF using N-Cadherin antibodies. The antibody may be any antagonising or neutralizing N-Cadherin antibody suitable for therapeutic use. | 2015-02-19 |
20150050241 | METHOD OF TREATING VIRAL INFECTIONS - The present invention is directed to methods and compositions employing 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine (“H2G”) or derivatives or analogs thereof for the treatment of viral diseases, as well as for the treatment of other conditions, including, but not limited to, cancer, chronic fatigue syndrome, Alzheimer's disease, multiple sclerosis and Graves' disease. The H2G or derivative or analog thereof can be administered in a pharmaceutical composition and can be administered with an additional antiviral therapeutic agent or another agent for the treatment of other conditions. | 2015-02-19 |
20150050242 | NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE - The present invention relates to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glycoproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatment of cancer or CNS disorders. | 2015-02-19 |
20150050243 | DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS - Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect. | 2015-02-19 |
20150050244 | Entomopathogenic Fungi and Uses Thereof - The present invention provides a strain of entomopathogenic | 2015-02-19 |
20150050245 | METHODS AND DELIVERY SYSTEM FOR BENEFICIAL ADDITIVE AND SUBTRACTIVE BIOLOGICAL AGENTS TO PROMOTE BALANCED MAMMALIAN GASTROINTESTINAL FLORA - This invention relates to controlled release formulations of probiotic bacteria and bacteriophages, including combined formulations of probiotic bacteria and bacteriophages. The formulations contain a hydrophilic agent, an electrolytic agent and a polysaccharide and may be in tablet form for oral delivery to the intestinal system. In one preferred aspect, the formulations of the present invention effect the simultaneous introduction or addition of probiotic bacteria and bacteriophages to cause the subtraction or removal of undesirable bacteria. | 2015-02-19 |
20150050246 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method may include a method of treating an infection. The method may comprise administering a microbiota restoration therapy composition to a patient with an infection. The microbiota restoration therapy composition may comprise a mixture of an effective amount of fecal microbiota and an effective amount of polyethylene glycol. | 2015-02-19 |
20150050247 | Natural Tissue-Derived Decellularized Matrix and Methods of Generating and Using Same - Decellularized tissue-derived extracellular matrices (ECM) and methods of generating and using same are provided. The method of generating a decellularized matrix includes the steps of: (a) subjecting the tissue to washes and a hypertonic buffer; (b) subjecting the tissue to an enzymatic proteolytic digestion with an enzyme such as trypsin; and (c) removing all cellular components from the tissue using a detergent solution which includes Triton-X-100 and ammonium hydroxide. Specifically, there is provided a decellularized myocardium-derived matrix which is completely devoid of all cellular components and hence non-immunogenic in a subject, exhibits suitable structural and mechanical properties for cardiac tissue engineering or replacement therapy of damaged cardiac tissue, and is capable of remodeling upon seeding of cells. | 2015-02-19 |
20150050248 | MULTIFUNCTIONAL IMMATURE DENTAL PULP STEM CELLS AND THERAPEUTIC APPLICATIONS - The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes. | 2015-02-19 |
20150050249 | ENHANCEMENT OF OSTEOGENIC POTENTIAL OF BONE GRAFTS - The present invention concerns the enhancement of the osteogenic potential of bone graft by ex vivo treatment with a Wnt polypeptide, such as a liposomal Wnt polypeptide. | 2015-02-19 |
20150050250 | CELL THERAPY TECHNOLOGY TO DELIVER RADIO-PROTECTIVE PEPTIDES - A method of reducing a symptom of radiation exposure in a subject is provided. The method includes a step of introducing mammalian cells into the subject, the mammalian cells having been treated ex vivo to insert therein a polynucleotide encoding polypeptide that is protective against radiation. The mammalian cells express in vivo in the subject a therapeutically effective amount of the polypeptide thereby reducing a symptom of radiation exposure. | 2015-02-19 |
20150050251 | Cosmetic Preparations - The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination. | 2015-02-19 |
20150050252 | PLURIPOTENT STEM CELLS AND METHOD OF STIMULATING AND EXTRACTING NON-EMBRYONIC PLURIPOTENT STEM CELLS FROM MAMMAL BLOOD AND USING RECONSTITUTED PLURIPOTENT STEM CELLS TO TREAT DISEASES INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Stimulating tissue resident pluripotent stem cells in a manner that the respective subject (e.g., human) acts as its own sterile bioreactor for in vivo stem cell proliferation thus eliminating the need to isolate, cultivate, maintain, proliferate and release stem cells ex vivo. The stimulation mobilizes excess pluripotent stem cells into the peripheral vasculature where the pluripotent stem cells can either migrate to damaged tissues and/or be harvested by simple venipuncture, thus eliminating potential morbidity and mortality elicited from harvesting tissue from solid tissue sites. The pluripotent stem cells are separated from the blood by gravity sedimentation, after which the pluripotent stem cells can easily be aspirated from the white blood cells and red blood cells. Billions of pluripotent stem cells can be generated in this fashion for infusion/injection into the body, via the vasculature, and into the organ(s) in need of tissue repair and regeneration. | 2015-02-19 |
20150050253 | CONTROLLED GROWTH OF MICROORGANISMS - It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types. | 2015-02-19 |
20150050254 | BACTERIAL STRAINS ISOLATED FROM PIGS - A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against | 2015-02-19 |
20150050255 | LACTOCOCCUS LACTIS STRAINS | 2015-02-19 |
20150050256 | Class I and II Lantibiotics from Geobacillus thermodenitrificans - The invention provides lantibiotics geobacillin I and geobacillin II from | 2015-02-19 |
20150050257 | FIBROSIS CAUSING AGENT - A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed. | 2015-02-19 |
20150050258 | NEMATOCIDAL COMPOSITION COMPRISING BACILLUS SUBTILIS AND BACILLUS LICHENIFORMIS - The present invention refers to a composition comprising | 2015-02-19 |
20150050259 | NUTRACEUTICAL MODULATORS OF STEM CELL ACTIVITY - The present invention relates to a nutraceutical formulation useful for increasing the concentrations of circulating stem cells in a mammal. Disclosed are compositions of matter for increasing the concentrations of circulating stem cells in the blood, consisting of a mixture of natural compounds comprising: ashwagandha, milk thistle, vitamin D3, fucoidan, and garcinia indica. One embodiment of the present invention describes a method for increasing circulating concentrations of stem cells in a mammal using an oral delivery vehicle containing said combination of natural compounds. | 2015-02-19 |
20150050260 | PYRROLOQUINOLINE QUINONE BASED COMPOSITIONS AND USES - The present invention provides pharmaceutical and dietary compositions in which pyrroloquinoline quinone (PQQ) and its derivatives are combined with other biologically active compounds to produce a synergistic beneficial effect beyond the effect produced by PQQ or its derivatives alone. The present invention also provides methods for providing various beneficial effects which comprise administering these compositions to a mammalian subject. | 2015-02-19 |
20150050261 | DIETARY AND NUTRITIONAL SUPPLEMENTS CONTAINING AN OMEGA-3 FATTY ACID OF PLANT-BASED ORIGIN AND A FOLATE DERIVATIVE - The present invention relates to dietary and nutritional supplements comprising various vitamins, minerals and nutrients, including an omega-3 fatty acid of plant-based origin and a folate derivative. | 2015-02-19 |
20150050262 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. | 2015-02-19 |
20150050263 | Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System - Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease. | 2015-02-19 |
20150050264 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF - The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | 2015-02-19 |
20150050265 | ANTI-MCPIP THERAPIES FOR OCULAR NEOVASCULARIZATION - There is provided a method of treating a condition in a subject in need characterized at least in part by abnormal, uncontrolled, undesirable or pathological ocular neovascularization. The method includes administering to the patient an effective amount of an interfering agent that inhibits the expression of MCPIP. | 2015-02-19 |
20150050266 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS - This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal. | 2015-02-19 |
20150050267 | ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME - The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. | 2015-02-19 |
20150050268 | PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING - Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling. | 2015-02-19 |
20150050269 | ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES - The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration. | 2015-02-19 |
20150050270 | ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS - The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg | 2015-02-19 |
20150050271 | JCV NEUTRALIZING ANTIBODIES - In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1. | 2015-02-19 |
20150050272 | METHOD OF DYNAMIC SPECTROSCOPY UNDER PHYSIOLOGICAL CONDITIONS - The present invention relates to the field of dynamic spectroscopy and more precisely to a method involving dynamic molecules spectroscopy technology designed to determine transitional changes in molecules conformation and assemblies both in physiologic and pathologic conditions. The method comprises in vitro fingerprints of a sample taken under highly controlled temperature in order to obtain precise images of either one or an ensemble of molecular dynamics. Due to its precise information, the method according to the invention allows shortening of the drug discovery stage. | 2015-02-19 |
20150050273 | AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES - The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided. | 2015-02-19 |
20150050274 | METHODS AND BIOMARKERS FOR DETECTION AND TREATMENT OF MATURE T-CELL LEUKEMIA - The present invention relates to methods and biomarkers for detection and characterization of mature T-cell neoplasias/leukemias (e.g., T-cell prolymphocytic leukemia, Sezary syndrome) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples). | 2015-02-19 |
20150050275 | PURIFICATION OF ANTI-C-MET ANTIBODIES - Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same. | 2015-02-19 |
20150050276 | High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B - Provided herein are antibodies that specifically bind and neutralize | 2015-02-19 |
20150050277 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES - Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition. | 2015-02-19 |
20150050278 | SOLUBLE ENGINEERED MONOMERIC FC - Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided. | 2015-02-19 |
20150050279 | B-CELL RECEPTOR COMPLEX BINDING PROTEINS CONTAINING T-CELL EPITOPES - The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of CD22, CD19, CD20, and CD21, and b) an immunogenic peptide comprising at least one T-cell epitope for use in vaccination of a subject against B-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same. It also relates to a method for the stimulation of antigen-specific T-cells, comprising a) contacting antigen presenting cells (APC) with a polypeptide, the polynucleotide, or the vector of the invention, b) contacting said APC with T-cells, and c) thereby stimulating antigen-specific T-cells specific for said at least one T-cell epitope; to a method for immunizing a subject against B-cell hyperproliferation, to a method for immunizing a subject against an infectious agent, and to a method for inducing tolerance in a subject. | 2015-02-19 |
20150050280 | SOLUBLE HUMAN M-CSF RECEPTOR AND USES THEREOF - Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided. | 2015-02-19 |
20150050281 | METHODS OF TREATING A TAUOPATHY - The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods. | 2015-02-19 |
20150050282 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X - The present invention relates to compounds derived from sugars which reproduce the epitopes of | 2015-02-19 |
20150050283 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER - The invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient. | 2015-02-19 |
20150050284 | ANTIBODY BINDING MICROBIAL HEPARIN BINDING MOTIF TO RETARD OR PREVENT MICROBIAL BIOFILM FORMATION ON IMPLANTED MEDICAL DEVICES - Methods and reagents for ameliorating biofilm formation on a surface of an indwelling or implanted device in a patient resulting in decreased virulence of microorganisms such as | 2015-02-19 |
20150050285 | Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates - Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or antifolates. | 2015-02-19 |
20150050286 | ANTI-NGF ANTIBODIES AND METHODS USING SAME - The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain. | 2015-02-19 |
20150050287 | ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME - Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13. | 2015-02-19 |
20150050288 | Treatment of TH17-Mediated Autoimmune Disease Via Inhibition of Stat3 - Methods for treating autoimmune disease using one or more inhibitor of STAT3 are provided herein. Also disclosed are methods for diagnosing and monitoring autoimmune disease or the propensity to develop autoimmune disease in a subject. The present invention demonstrates that inhibition of STAT3 prevents development of autoimmune disease in vivo. Based on this finding, Stat3 inhibitors can be used to treat and/or diagnose autoimmune disease in a subject. | 2015-02-19 |